Global markets are witnessing a wave of significant corporate restructuring as companies across the pharmaceutical, health, and automotive sectors pursue strategic mergers and acquisitions. From high-profile private equity buyouts to cross-border industry consolidations, these deals reflect a broader ambition to accelerate international growth, enhance innovation, and scale operational capabilities.
Key takeaways
- Bain Capital has acquired the UK-based vitamin giant Vitabiotics in a deal reportedly worth £900 million.
- Aurobindo Pharma’s subsidiary, Apitoria, is purchasing an 80% stake in A1 Biochem to bolster its research and development platform.
- Subscription car service Carbar is merging with UAE-based Carasti to create a combined entity seeking $10 million in new capital.
Private equity drives health sector growth
The vitamin and supplement industry has seen a major shake-up following the acquisition of Vitabiotics by US investment firm Bain Capital. Vitabiotics, founded in 1971 and previously led by former Dragons’ Den star Tej Lalvani, has become the UK’s largest vitamin manufacturer. The deal, valued at approximately £900 million, aims to leverage Bain Capital’s global expertise to drive rapid international expansion. While the Lalvani family has exited, the company has confirmed there will be no immediate changes to day-to-day operations, ensuring continuity for its popular brands such as Perfectil and Pregnacare.
Pharmaceutical research capabilities expand
Aurobindo Pharma Limited has announced a strategic move to strengthen its position in the pharmaceutical value chain. Its subsidiary, Apitoria Pharma, has agreed to acquire an 80% stake in the Contract Research Services (CRO) business of A1 Biochem Group for $17 million. This acquisition is designed to establish a dedicated Contract Research, Development and Manufacturing Organization (CRDMO) platform. By integrating A1 Biochem’s research capabilities—which include medicinal chemistry and rapid process scale-up—Aurobindo aims to enhance its service offerings for biotechnology firms and pharmaceutical partners globally.
Automotive sector embraces the subscription model
The automotive industry is evolving as subscription-based models gain traction. Australian-based car subscription service Carbar is set to merge with its Middle Eastern rival, Carasti. This strategic combination aims to create a larger, more competitive entity with a fleet of over 3,000 vehicles, doubling Carbar’s current capacity. The newly merged business is actively seeking $10 million in fresh capital to support its global growth ambitions. This merger highlights the shift towards flexible, modern transport solutions that provide consumers with alternatives to traditional vehicle ownership.
Sources
- Dragon’s Den star’s vitamins business bought by US firm Bain, London Evening Standard.
- Dragons’ Den star sells business for £1,000,000,000 5 years after leaving show, Metro.co.uk.
- Aurobindo Pharma’s Apitoria to Acquire 80% Stake in A1 Biochem CRO Business for USD 17 Million, Medical Dialogues.
- Subscription car business Carbar seeks $10m for merger with UAE’s Carasti, AFR.
